eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2016
vol. 12
 
Share:
Share:
more
 
 
abstract:
State of the art paper

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls

Paweł Gut, Agata Czarnywojtek, Jakub Fischbach, Maciej Bączyk, Katarzyna Ziemnicka, Elżbieta Wrotkowska, Maria Gryczyńska, Marek Ruchała

Arch Med Sci 2016; 12, 1: 1–9
Online publish date: 2016/02/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration.
keywords:

chromogranin A, neuroendocrine tumors

references:
Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C-1C.
Blaschko H, Comline RS, Schneider FH, et al. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchic stimulation. Nature 1967; 215: 58-9.
Gallo MP, Levi R, Ramella R, et al. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in the rat ventricular myocardium. Am J Physiol 2007; 292: H2906-12.
Fasciotto BH, Trauss CA, Greeley GH, et al. Parastatin (porcine chromogranin A347-419), a novel chromogranin-derived peptide, inhibits paratharoid cell secretion. Endocrinology 1993; 133: 461-6.
Helman LJ, Ahn TG, Levine MA, et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem 1988; 263: 11559-63.
Taylor CV, Taupenot L, Mahata SK, et al. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem 2000; 275: 22905-15.
Bilek R, Safarik L, Ciprova P. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res 2008; 57 (Suppl. 1): S171-9.
Cetin Y, Aunis D, Bader MF, et al. Chromostatin, a chromogranin A-derived bioactive peptide, is present in human pancreatic insulin (beta) cells. Proc Natl Acad Sci USA 1993; 90: 2360-4.
Glinicki P, Kapuścińska R, Jeske W. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods. Endokrynol Pol 2010; 61: 346-50.
Stridsberg M, Eriksson B, Oberg K, et al. A comparison between three commercial kits for chromogranin a measurements. J Endocrinol 2003; 177: 337-41.
Ardill JE, O’Dorosio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease an as prognostic indicators. Endocrinol Metab Clin N Am 2010; 39: 777-90.
Pregun I, Herszenyi L, Juhasz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin A level. Digestion 2011; 84: 22-8.
Hsiao RJ, Mezger MS, O’Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955-64.
Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin in heart failure: a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23: 967-74.
Nicholls DP, Onuoha GN, McDowell G, et al. Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol 1996; 91 (Suppl. 1): 13-20.
Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin a in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28: 1117-27.
Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27: 4293-9.
Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndrome. Eur Heart J 2009; 30: 25-32.
DiComte G, Rossi CM, Marinosci A, et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthitis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85: 81-7.
Sciola V, Massironi S, Conte D, et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 867-71.
Valeur J, Milde AM, Helle KB, et al. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43: 1403-4.
Fossmark R, Jianu CS, Martinsen TC, et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43: 20-4.
Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 2011; 40: 111-34.
Nobels FR, Kwekkeboom BJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alfa-subunit of glycoprotein hormones. J Clin Endocr Metab 1997; 82: 2622-8.
Adolf K, Wagner L, Bergh A, et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472-84.
Tropea F, Baldari S, Restifo G, et al. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin Drug Investig 2006; 26: 715-22.
Molina R, Alvarez E, Aniel-Quiroga A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biol 2011; 32: 13-22.
Louthan O. Chromogranin A in physiology and oncology. Folia Biologica (Praha) 2011; 57: 173-81.
Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D, et al. Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2008; 59: 41-56.
Tomasetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-8.
Janson ET, Holmberg L, Strisberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a refferal center. Ann Oncol 1997; 8: 685-90.
Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med 1989; 320: 444-7.
Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as a marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-7.
Walter T, Chardon L, Chopin-Laly X, et al. Is the combinantion of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer 2012; 48: 1766-73.
Nobels FR, Kwekkeboom DJ, Bouillon R, et al. Chromogranin A: its clinical value as a marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28: 431-40.
Ferrari L, Seregni E, Lucignani G, et al. Accuracy and clinical correlates of two different methods for chromogranin assay in neuroendocrine tumours. Int J Biol Markers 2004; 19: 295-304.
Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A- biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-43.
Vinik AI, Silva MP, Woltering G, et al. Biochemical testing for neuroendocrine tumors. Pancreas 2009; 38: 876-89.
O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20: 1-12.
Nehar D, Lombard-Bohas C, Olivieri S, et al. Serum chromogranin A for diagnosis and follow-up of endocrine tumors. Clin Endocrinol (Oxf) 2004; 60: 644-52.
Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumours treated at a single institution. Clin Cancer Res 2008; 14: 7789-803.
Korse CM, Bonfrer JM, Aaronson NK, et al. Chromogranin A as an alternative to 5-hydroxyindolaecetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 2009; 89: 296-301.
Welin S, Strisberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89: 302-7.
Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin, neuron specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86: 858-65.
Eriksson B, Arnberg H, Oberg K, et al. Chromogranins – new sensitive markers for neuroendocrine tumors. Acta Oncol 1989; 28: 325-9.
Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment and prognosis with gastric carcinoids. Gut 1998; 43: 223-8.
Stivanello M, Berutti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 (Suppl. 2): S73-7.
Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-43.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177-Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-62.
Olausson M, Friman S, Herlenius G, et al. Orthotropic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13: 327-33.
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
Srivastava A, Padilla O, Fischer-Colbrie R, et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol 2004; 28: 1371-8.
Nobels FR, de Herder WW, Kwekkeboom DJ, et al. Serum chromogranin A in the differential diagnosis of Cushing’s syndrome. Eur J Endocrinol 1994; 131: 589-93.
Feng C, Li HZ, Yan WG, et al. The expression and significance of chromogranin A and synaptophysin in adrenal gland tumors. Zhonghua Zhong Liu Za Zhi 2005; 27: 486-8.
Portela-Gomes GM, Stridsberg M, Grimelius L, et al. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immunohistochemical study with region-specific antibodies. APMIS 2004; 112: 663-73.
Giovanella L, Squin N, Ghelfo A, et al. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 2006; 50: 344-7.
D’Herbomez M, Gouze V, Huglo D, et al. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 2001; 42: 993-7.
Bernini GP, Moretti A, Borgioli M, et al. Plasma and tissue chromogranin in patients with adrenocortical adenomas. J Endocrinol Invest 2004; 27: 821-5.
Schurman G, Raeth U, Wiedenmann B, et al. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992; 16: 697-701.
Baudin E, Bihart JM, Bachelot A, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001; 12: S79-82.
Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia. An Italian Multicenter Study. Endocr Relat Cancer 2007; 14: 473-82.
Nikou GC, Marinou K, Thomakos P, et al. Chromogranin A levels in diagnosis treatment and follow up of 42 patients with non functioning pancreatic endocrine tumors. Pancreatology 2008; 8: 510-9.
Namwongprom S, Wong FC, Tateishi U, et al. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tomours. Ann Nucl Med 2008; 22: 237-43.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe